Product Description
for the Treatment of Evaporative Dry Eye (Sourced from: https://clinicaltrials.gov/ct2/show/NCT02965846)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AbbVie
Company Location: Eastern America
Company CEO: Richard A. Gonzalez
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Keratoconjunctivitis Sicca|Dry Eye Syndromes
Phase 2: Meibomian Gland Dysfunction
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01633788 |
NCT01633788 | P2 |
Completed |
Meibomian Gland Dysfunction |
2015-02-05 |
2019-03-19 |
Treatments |
|
NCT02815293 |
NCT02815293 | P3 |
Terminated |
Dry Eye Syndromes|Keratoconjunctivitis Sicca |
2017-06-21 |
2019-03-20 |
Treatments |
|
NCT02965846 |
NCT02965846 | P3 |
Terminated |
Keratoconjunctivitis Sicca|Dry Eye Syndromes |
2017-06-13 |
2019-03-21 |
Recent News Events
Date |
Type |
Title |
|---|